CVS Caremark Settles FTC Insulin Price Inflation Allegations
- July 17, 2026
- Written by AHLA Legal Staff
CVS Health’s Caremark LLC has reached a settlement with the Federal Trade Commission (FTC) to resolve allegations that the pharmacy benefit manager (PBM) engaged in unfair rebate practices that artificially inflated insulin list prices.
ARTICLE TAGS
You must be logged in to access this content.